ER+ BREAST CANCER
Clinical trials for ER+ BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new ER+ BREAST CANCER trials appear
Sign up with your email to follow new studies for ER+ BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo shows promise for Hard-to-Treat breast cancer
Disease control OngoingThis phase 2 study tests whether adding the experimental drug ipatasertib to standard hormone therapy and a targeted drug can help people with a specific type of advanced breast cancer (ER+/HER2-) live longer without their cancer growing. The study includes 57 participants whose …
Matched conditions: ER+ BREAST CANCER
Phase: PHASE2 • Sponsor: Royal Marsden NHS Foundation Trust • Aim: Disease control
Last updated May 17, 2026 02:20 UTC
-
New combo therapy targets Hard-to-Treat cancers in early trial
Disease control OngoingThis early-phase trial tests a combination of two drugs, naptumomab estafenatox and durvalumab, in 120 adults with advanced or metastatic solid tumors (like breast, ovarian, lung, and pancreatic cancers) that have no curative options. The main goal is to find safe doses and under…
Matched conditions: ER+ BREAST CANCER
Phase: PHASE1 • Sponsor: NeoTX Therapeutics Ltd. • Aim: Disease control
Last updated May 17, 2026 02:08 UTC
-
New drug targets Cancer's 'Extra DNA' in early trial
Disease control OngoingThis early-phase study tests an experimental oral drug, BBI-355, in people with advanced solid tumors (like certain breast, ovarian, lung, and other cancers) that have extra copies of certain genes (oncogene amplifications). The study aims to find the safest dose and see if BBI-3…
Matched conditions: ER+ BREAST CANCER
Phase: PHASE1 • Sponsor: Boundless Bio, Inc. • Aim: Disease control
Last updated May 17, 2026 02:03 UTC
-
New targeted radiation therapy shows promise for tough breast cancer
Disease control OngoingThis early-phase trial tests a drug called RYZ101 in people with a specific type of advanced breast cancer (ER+, HER2-) that has not responded to other treatments. The drug delivers radiation directly to cancer cells that have a certain marker (SSTR). The goal is to see if it is …
Matched conditions: ER+ BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: RayzeBio, Inc. • Aim: Disease control
Last updated May 07, 2026 18:40 UTC